Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Annual Business Results
May 26, 2003
- DIAGNOSTIC NEWS IN BRIEF
May 26, 2003
- Kissei Aims to Increase Sales, 1.3 Times by 2008: New Management Plan
May 26, 2003
- Annual Business Results
May 26, 2003
- WORLD NEWS IN BRIEF
May 26, 2003
- Takara Bio to Promote Anti-cancer Immunotherapy via JV
May 26, 2003
- MPC to Create Marketing Subsidiary in Germany
May 19, 2003
- Health Promotion Law to Help Optimize Medical Spending: HSB Head
May 19, 2003
- Ethical Drug Sales Rose 3.7% in FY2002: CR&C Report
May 19, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 19, 2003
- BUSINESS NEWS IN BRIEF
May 19, 2003
- Yamanouchi's YM905 Effective for Pollakiuria: AUA Meeting
May 19, 2003
- NEW PRODUCTS
May 19, 2003
- Nu-Lotan Prevents Diabetes in Hypertensive Patients: Banyu Symposium
May 19, 2003
- Daiichi: R&D Spending, NHI Price Cuts Hit Sales, Profits
May 19, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 19, 2003
- Teijin: Pharma Sales Down 2.2% to \92.5 Bil.
May 19, 2003
- GENKY Stores to Go Public Next Month
May 19, 2003
- Freund: Sales Down 12.3%, Net Profits Down 94.7%
May 19, 2003
- DIAGNOSTIC NEWS IN BRIEF
May 19, 2003
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…